Streamline your COVID-19 testing and reporting...

With the BD Veritor™ Plus System* and ImageMover app

As you continue to navigate the ever-changing complexities of COVID-19, having the right tools can help you scale testing as needed. The faster you detect a pathogen, the sooner you can respond and limit its spread. The **BD Veritor™ Plus System**, combined with the **ImageMover app**, offers you a simple, reliable and flexible HIPAA-compliant[3] solution to fit your needs. Whether used for asymptomatic serial testing or only on symptomatic individuals, you can be confident that you are doing all you can to move forward as safely as possible.

Designed to work with you and for you—at every step

1 Easy registration



Get started quickly by pre-loading lists of test subjects or collect demographic information through the app and obtain consent

Reduce paperwork by scanning driver's licenses to pre-populate information for on-site registration

Streamline the process by printing unique barcodes for each test where needed

2 Rapid, reliable results

Minimize wait times with reliable results for SARS-CoV-2 in 15 minutes[1]

Securely capture and store test results

Expand testing with online training, easy-to-read display and single-button functionality

3 Timely reporting

Build confidence by securely providing patients with result

Stay compliant by auto-submitting daily reports to the U.S. HHS, as required[2]

Minimize manual transcription by downloading .CSV report outputs

For more information, contact your local BD or distributor representative.

*The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

- This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
- This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

References:

1. ImageMoverMD Solution. CONNECT DISPARATE IMAGING SYSTEMS. Accessed on May 6, 2021 at https://www.imagemovermd.com/our-solution.
2. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2. Package insert. Sparks, MD. Becton, Dickinson and Company. 2021.
3. U.S. Department of Health & Human Services. *HHS Announces New Laboratory Data Reporting Guidance for COVID-19 Testing.* Accessed February 16, 2021, at https://www.hhs.gov/about/news/2020/06/04/hhs-announces-new-laboratory-data-reporting-guidance-for-covid-19-testing.html. Published June 4, 2020. Updated September 23, 2020.

BDVeritor.com